Recombinant Human CD22 protein (Myc Tag, His Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

Myc Tag, His Tag

Activity

not tested

Cat no : Eg0200



Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Human CD22 protein Asp20-Arg687 (Accession# P20273-1) with a Myc tag and a His tag at the C-terminus.
GeneID 933
Accession P20273-1
PredictedSize 80.1 kDa
SDS-PAGE 90-120 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CD22, also known as Siglec-2 (sialic acid binding Ig-like lectin 2) or BL-CAM (B-lymphocyte cell adhesion molecule), is a 130-140 kDa, B-cell restricted, type I transmembrane glycoprotein belonging to the immunoglobulin gene superfamily. The expression of CD22 is developmentally regulated. It is expressed at low levels in the cytoplasm of pro-B and pre-B cells and present on the cell surface only at mature stages of B-cell differentiation. Cell surface expression is lost during terminal differentiation into plasma cell and after B-cell activation. CD22 is an inhibitory receptor for B-cell receptor (BCR) signalling, preferentially binds to alpha-2,6-linked sialic acid and mediates B-cell B-cell interactions. It plays a crucial role in activation and differentiation of the B-cell.

References:

1. Clark EA, et al. (1993) J Immunol. 150(11):4715-8. 2. Nitschke L, et al. (1997) Curr Biol. 7(2):133-43. 3. Carnahan J, et al. (2003) Clin Cancer Res. 9(10 Pt 2):3982S-90S.